During the COVID-19 pandemic, governments imposed home confinement and school-based learning was the normal. Has this caused more myopia? In this clinical case, the unique environment of lockdown is explored in view of myopia management outcomes.
An 8-year-old child is essentially monocular, due to unilateral high myopia associated with coloboma. The normally sighted eye has low myopia. How should we best balance safety and proactive myopia control in such a case?
Unilateral myopia can present a challenge to both myopia correction and control choices. In this case study, learn about which interventions have evidence for myopia control and reducing anisometropia, as well as the considerations for monocular versus binocular correction and treatment.
Atropine is a treatment for myopia control, but do combination treatments such as with orthokeratology increase the efficacy? Learn about how well it works, which concentration, for whom it works best, side effects, treatment duration and more.
In this clinical case, the practitioner is considering whether to start a young patient on a monotherapy or go straight to combination treatment. The discussion includes the recent studies on combination treatment and the best approach for utilizing atropine in view of orthokeratology wear.
Atropine has been the apparent hero of myopia management since the 2006 ATOM1 study, and since then, low concentration 0.01% atropine has become the new hero and then fallen out of favour. This article describes how lower concentrations work to balance efficacy and side effects, which should we select now, and what newer research on formulations and combinations can tell us.
Retinal detachment is not a condition which only affects adults. This case of a 12-year-old high myope with an asymptomatic retinal detachment and hole forms the basis for discussion of factors, frequency of types and treatment outcomes in childhood retinal detachment. The myopia control strategy is also discussed.
Myopia control is vital for children with fast myopia progression. What are the key risk factors for faster myopia progression? What clinical findings indicate a more proactive myopia management strategy may be required? This case describes risk factors and evidence-based treatment options for fast myopia progressors.
MiSight 1 day is a dual focus contact lens – it’s not a multifocal as it does not provide an ‘add’ at near. When considering a first correction for a young myope, how should we prioritize both myopia correction and control? Read more in this case.
Contact lenses offer numerous functional, psychological and myopia controlling benefits for children. What should you do if a parent or patient says no to contact lenses for their child, and you consider it an ideal option? How can you approach communication to convey the safety and benefits?
